Development and assessment of novel assays to predict response to second-line TKI therapy in imatinib-resistant CML [ 2009 - 2011 ]

Research Grant

Researchers: Prof Timothy Hughes (Principal investigator) ,  A/Pr Susan Branford ,  Prof Deborah White ,  Prof Junia Vaz De Melo

Brief description Patients with chronic myeloid leukaemia (CML) respond well to imatinib, the first small molecule developed to block the kinase activity of the causative oncogene in CML, BCR-ABL. However some patients develop resistance. Several new kinase inhibitors are now available that are effective in some patients with imatinib resistance. We plan to develop biological and molecular assays to predict if a CML patient will respond to a specific second-line kinase inhibitor to optimise second-line therapy.

Funding Amount $AUD 491,308.03

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant